Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
HTD1801 capsules, 250mg
UDCA capsules, 125mg
change in gamma-glutamyl transferase (GGT)
Time frame: 18 weeks
percentage of patients whose GGT normalizes to <50 units/liter
Time frame: 18 weeks
change in aspartate aminotransferase (AST)
Time frame: 18 weeks
change in alanine aminotransferase (ALT)
Time frame: 18 weeks
change in alkaline phosphatase (ALP)
Time frame: 18 weeks
change in total bilirubin
Time frame: 18 weeks
change in C-reactive protein (CRP)
Time frame: 18 weeks
incidence of adverse events
Time frame: 18 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.